NASDAQ · AURA
Healthcare · Biotechnology
$6.09
Up+$0.05 (+0.83%)
Updated Oct 3, 2026, 12:22 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AURA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
AURA closed at $6.09 after 20 trading sessions, down 19.44% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $6.11 | $6.15 | $5.97 | $6.09 | 2.1M |
| Oct 1, 2026 | $6.36 | $6.36 | $6.00 | $6.04 | 807.35K |
| Sep 30, 2026 | $6.21 | $6.36 | $6.12 | $6.28 | 677.46K |
| Sep 29, 2026 | $6.13 | $6.175 | $6.04 | $6.15 | 795.45K |
| Sep 28, 2026 | $6.03 | $6.17 | $6.00 | $6.15 | 483.66K |
| Sep 25, 2026 | $6.18 | $6.18 | $5.985 | $6.00 | 1.12M |
| Sep 24, 2026 | $6.01 | $6.25 | $5.95 | $6.15 | 963.08K |
| Sep 23, 2026 | $6.42 | $6.4699 | $5.98 | $6.02 | 1.04M |
| Sep 22, 2026 | $6.32 | $6.46 | $6.27 | $6.45 | 601.58K |
| Sep 21, 2026 | $6.52 | $6.54 | $6.25 | $6.36 | 819.1K |
| Sep 18, 2026 | $6.73 | $6.73 | $6.43 | $6.44 | 3.78M |
| Sep 17, 2026 | $6.84 | $6.88 | $6.46 | $6.59 | 916.38K |
| Sep 16, 2026 | $6.92 | $7.01 | $6.59 | $6.73 | 1.29M |
| Sep 15, 2026 | $7.11 | $7.11 | $6.605 | $6.92 | 712.29K |
| Sep 14, 2026 | $7.14 | $7.16 | $6.94 | $7.01 | 467.42K |
| Sep 11, 2026 | $7.08 | $7.08 | $6.91 | $6.995 | 830.85K |
| Sep 10, 2026 | $7.14 | $7.195 | $6.93 | $6.99 | 785.54K |
| Sep 9, 2026 | $7.34 | $7.39 | $7.16 | $7.20 | 465.9K |
| Sep 8, 2026 | $7.48 | $7.56 | $7.28 | $7.36 | 507.75K |
| Sep 4, 2026 | $7.30 | $7.57 | $7.30 | $7.56 | 456.4K |
The latest Smart Investors Daily articles mentioning AURA.
Company
Market Activity
Research & News
AURA research
Company profile and research snapshot.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 29, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 30, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 26, 2025 | Evercore ISI Group | Outperform | — |
| Aug 13, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 16, 2026
Aura Biosciences, Inc. (AURA) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 2:35 PM EDTCompany ParticipantsNatalie Holles -...
Yahoo · Sep 6, 2026
How Aura Investments Stock Is Reacting To Mixed Earnings And A New Dividend Aura Investments (TASE:AURA) has drawn fresh attention after second quarter and half year results showed higher revenue alongside lower net income and earnings per share, paired with a recently updated cash dividend announcement. At a share price of ₪19.7, Aura Investments has seen a 34.29% 1 month share price return and 11.05% 7 day share price return following the earnings and dividend updates, while the share price...
Yahoo · Sep 2, 2026
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.Fireside Chat at 2:35 p.m. ET The live webcast of the fireside chat will
Yahoo · Sep 1, 2026
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new C
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AURA.
